Immunic Appoints Erik Lundgren as CEO with Significant Equity Grant; Former CEO Transitions to Scientific Strategy
Summary
Immunic, Inc. appointed Erik Lundgren, a biopharmaceutical veteran with MS commercialization expertise, as its new CEO, while former CEO Daniel Vitt transitioned to a scientific strategy role on the Board. The new CEO received a substantial equity grant of 1,000,000 stock options.
Key Events
-
New CEO Appointed
Erik Lundgren, formerly Senior VP at Genentech, was appointed Chief Executive Officer, effective June 1, 2026. He brings nearly two decades of biopharmaceutical experience, including a key role in the launch of Ocrevus® for multiple sclerosis.
-
Former CEO Transitions to Scientific Strategy
Dr. Daniel Vitt resigned as CEO, effective June 1, 2026, but will continue to serve on the Board and retain responsibility for scientific strategy and portfolio advancement. His resignation was not due to any disagreement with the company.
-
Significant Equity Grant to New CEO
Mr. Lundgren received an initial equity option to purchase 1,000,000 shares of common stock, vesting over four years. This grant represents approximately 7.44% potential dilution based on current outstanding shares.
-
Executive Compensation Details
Mr. Lundgren's compensation includes a yearly base salary of $685,000, a guaranteed annual bonus of at least 60% of base salary for 2026, a $250,000 cash signing bonus, and a contingent $200,000 retention bonus.
Analysis
Immunic, a late-stage biotechnology company, has appointed Erik Lundgren as its new Chief Executive Officer. Mr. Lundgren brings extensive experience in biopharmaceutical commercial strategy, including a key role in the launch of Ocrevus® for multiple sclerosis, which aligns with Immunic's lead asset, vidofludimus calcium, currently in Phase 3 trials for MS. This strategic appointment aims to guide the company towards potential commercialization. While the former CEO, Dr. Daniel Vitt, has transitioned to a scientific strategy role and remains on the Board, mitigating the impact of his departure, the new CEO's compensation package includes options to purchase 1,000,000 shares. This represents a substantial potential dilution of approximately 7.44% of the company's current outstanding shares, which is a significant consideration for existing shareholders.
At the time of this filing, IMUX was trading at $13.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $176.7M. The 52-week trading range was $5.06 to $15.10. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.